Corvus Pharmaceuticals
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $246 |
Gross Profit | -21 | -23 | 218 | |
EBITDA | -7,234 | -5,912 | -6,230 | -5,601 |
EBIT | -7,255 | -5,933 | -6,253 | -5,629 |
Net Income | -40,217 | -4,262 | -5,701 | -6,653 |
Net Change In Cash | 0 | 0 | 0 | 246 |
Free Cash Flow | -6,321 | -5,481 | -5,157 | -5,167 |
Cash | 4,680 | 14,841 | 7,456 | 12,620 |
Basic Shares | 66,701 | 59,710 | 49,038 | 49,038 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -151 | -367 | -460 | -632 |
EBITDA | -26,878 | -40,940 | -42,781 | -43,128 |
EBIT | -27,029 | -41,307 | -43,241 | -43,760 |
Net Income | -27,029 | -50,049 | -38,200 | -4,823 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Cost of Revenue | 11,301 | |||
Free Cash Flow | -23,969 | -27,292 | -36,720 | -34,854 |
Cash | 12,620 | 13,159 | 63,458 | 16,455 |
Basic Shares | 48,025 | 46,553 | 41,854 | 29,478 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.60 |
2024-06-30 | -$0.04 |
2024-03-31 | -$0.12 |
2023-12-31 | -$0.14 |
